Amkay Products Ltd
₹ 48.0
0.00%
13 Nov
- close price
About
Incorporated in 2007, Amkay Products Ltd manufactures personalized healthcare products[1]
Key Points
- Market Cap ₹ 41.6 Cr.
- Current Price ₹ 48.0
- High / Low ₹ 68.6 / 36.0
- Stock P/E 11.9
- Book Value ₹ 30.1
- Dividend Yield 0.00 %
- ROCE 16.9 %
- ROE 14.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.77% over past five years.
- Working capital days have increased from 71.4 days to 104 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 26.41 | 40.63 | 36.47 | 27.86 | 31.07 | 38.39 | 43.56 | |
| 24.82 | 36.14 | 33.78 | 24.93 | 27.74 | 34.26 | 38.85 | |
| Operating Profit | 1.59 | 4.49 | 2.69 | 2.93 | 3.33 | 4.13 | 4.71 |
| OPM % | 6.02% | 11.05% | 7.38% | 10.52% | 10.72% | 10.76% | 10.81% |
| 0.04 | 0.10 | 0.29 | 0.46 | 1.25 | 1.32 | 0.98 | |
| Interest | 0.47 | 0.24 | 0.41 | 0.47 | 0.52 | 0.32 | 0.39 |
| Depreciation | 0.52 | 0.51 | 0.54 | 0.69 | 0.56 | 0.83 | 0.92 |
| Profit before tax | 0.64 | 3.84 | 2.03 | 2.23 | 3.50 | 4.30 | 4.38 |
| Tax % | 25.00% | 25.00% | 28.08% | 30.49% | 24.86% | 22.33% | |
| 0.48 | 2.88 | 1.47 | 1.55 | 2.63 | 3.34 | 3.48 | |
| EPS in Rs | 173.29 | 1,039.71 | 530.69 | 559.57 | 4.13 | 3.86 | 4.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 2% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 20% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 18% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.28 | 0.28 | 0.28 | 0.28 | 6.36 | 8.66 | 8.66 |
| Reserves | 2.42 | 5.67 | 5.93 | 7.10 | 3.64 | 15.41 | 17.38 |
| 1.62 | 0.42 | 4.33 | 4.70 | 5.47 | 2.64 | 1.90 | |
| 2.55 | 7.69 | 5.26 | 2.90 | 2.47 | 3.18 | 3.42 | |
| Total Liabilities | 6.87 | 14.06 | 15.80 | 14.98 | 17.94 | 29.89 | 31.36 |
| 0.00 | 0.00 | 3.91 | 2.40 | 2.58 | 4.14 | 3.99 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
| Investments | 0.00 | 0.40 | 2.79 | 3.62 | 2.57 | 6.85 | 6.27 |
| 6.87 | 13.66 | 9.10 | 8.96 | 12.79 | 18.78 | 21.10 | |
| Total Assets | 6.87 | 14.06 | 15.80 | 14.98 | 17.94 | 29.89 | 31.36 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.00 | 0.00 | -0.25 | 0.01 | -0.66 | -0.32 | |
| 0.00 | 0.00 | -3.07 | -0.34 | 0.48 | -5.84 | |
| 0.00 | 0.00 | 2.59 | 0.31 | 0.24 | 7.59 | |
| Net Cash Flow | 0.00 | 0.00 | -0.72 | -0.01 | 0.06 | 1.43 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 31.23 | 40.43 | 36.33 | 48.47 | 46.87 | 57.14 |
| Inventory Days | 4.54 | 4.18 | 28.03 | 46.61 | 92.57 | 112.95 |
| Days Payable | 41.76 | 82.57 | 64.42 | 44.46 | 33.99 | 36.44 |
| Cash Conversion Cycle | -5.98 | -37.96 | -0.06 | 50.62 | 105.45 | 133.65 |
| Working Capital Days | 10.78 | -8.62 | 21.12 | 54.11 | 56.15 | 103.92 |
| ROCE % | 76.33% | 28.86% | 20.87% | 22.36% | 16.88% |
Documents
Announcements
-
Unaudited Financial Result For The Half Year Ended September 30, 2025
1d - Unaudited H1 FY2025 results: revenue Rs2340.45L, PBT Rs268.80L, PAT Rs196.80L, EPS Rs2.33; LR unmodified.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday, 12Th November, 2025 For Consider And Approve The Unaudited Financial Result For The Half Year Ended September 30, 2025
1d - Unaudited half-year results ended 30 Sep 2025: Revenue Rs2,340.45L; PAT Rs196.80L; EPS Rs2.33; limited review unmodified.
-
Board Meeting Intimation for Consider And Approve The Unaudited Financial Result For The Half Year Ended September 30, 2025
6 Nov - Board meeting on Nov 12, 2025 to approve unaudited H1 results for period ended Sep 30, 2025.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - AGM on Sept 29, 2025: three ordinary resolutions passed; scrutinizer report dated Oct 1, 2025.
Business Overview:[1][2]
APL manufactures medical devices, disposables and other Healthcare Products like Face Mask, Alcohol Swabs, Lancet Needles, Nebulizer, Pulse Oximeter, Surgeon cap etc. These are used by healthcare centres, hospitals, nursing homes etc., under the brand name Amkay.
APL is the largest manufacturer of Blood Lancet Needles - Steel/Plastic in India. They have 50+ SKUs and 1000+ Distributors